{
    "Clinical Trial ID": "NCT00407888",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I",
        "  Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.",
        "  doxorubicin hydrochloride: Given IV",
        "  cyclophosphamide: Given orally",
        "  filgrastim: Given SC",
        "  paclitaxel albumin-stabilized nanoparticle formulation: Given IV",
        "  trastuzumab: Given IV",
        "  laboratory biomarker analysis: Correlative studies",
        "  quality-of-life assessment: Ancillary studies"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Have a histologically confirmed diagnosis of primary breast carcinoma that has been surgically resected; (this regimen is not intended for neoadjuvant treatment)",
        "  4 + nodes",
        "  OR if 1-3 + nodes, either ER OR HER-2/neu+",
        "  OR have high-risk node negative disease that is HER-2/neu positive OR >= 2.0 cm tumor size",
        "  HER-2/new + definition: patient has known tumor HER-2/new expression = 3+ by IHC or, if 2+ by IHC confirmed to be FISH positive",
        "  Patients with clinically apparent cardiac disease, or history of same, are not eligible; patients who are >= 60 years of age or who have a history of hypertension must have an echocardiogram or MUGA prior to enrollment; patients with breast cancer that is HER-2/neu positive and a treatment plan that includes Herceptin must have an echocardiogram or MUGA scan prior to enrollment; the LVEF must be within the institutional normal range; if LVEF is > 75%, the investigator should consider having the LVEF reviewed or repeating the MUGA prior to registration",
        "  WBC >= 4,000",
        "  ANC >= 1,500",
        "  Platelet count >= 100,000",
        "  Serum creatinine =< 1.5 x IULN",
        "  Bilirubin =< 2.0",
        "  SGOT/SGPT/alkaline phosphatase =< 2 x IULN",
        "  Elevations greater than these require metastatic work up",
        "  Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific screening procedures",
        "Exclusion Criteria:",
        "  Except for the following, no other malignancy is allowed: synchronous ipsilateral breast cancer of the same subtype (ER/PR, HER-2/neu), adequately treated basal cell or squamous cell skin cancer, in situcervical cancer or other stage I or II cancer from which the patient has been disease free for at least 5 years",
        "  Patients with cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin are not eligible; this includes:",
        "  Angina pectoris that requires the use of antianginal medication",
        "  Cardiac arrhythmia requiring medication",
        "  Severe conduction abnormality",
        "  Clinically significant valvular disease",
        "  Cardiomegaly on chest x-ray",
        "  Ventricular hypertrophy on EKG",
        "  Uncontrolled hypertension, (diastolic greater than 100 mm/Hg or systolic > 200 mm/hg)",
        "  Current use of digitalis or beta blockers for CHF",
        "  Clinically significant pericardial effusion",
        "  Myocardial infarction documented as a clinical diagnosis or by EKG or any other test",
        "  Documented congestive heart failure",
        "  Documented cardiomyopathy",
        "  Documented arrhythmia or cardiac valvular disease that requires medication or is medically significant",
        "  Patients who have received prior chemotherapy or radiotherapy are not eligible",
        "  Patients who are pregnant or breastfeeding are not eligible; women of child bearing potential must agree to practice adequate contraception",
        "  Patients with active infection are not eligible",
        "  Patients who are known to be infected with HIV, hepatitis B or hepatitis C are not eligible; testing is not required unless there is a high index of clinical suspicion",
        "  Patients suffering from psychiatric impairment are not eligible"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival Following a Dose-intensive Weekly Regimen of Adriamycin + Oral Cyclophosphamide Augmented With G-CSF Support Followed by Abraxane and Herceptin",
        "  [Not Specified]",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Arm I",
        "  Arm/Group Description: Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.",
        "  doxorubicin hydrochloride: Given IV",
        "  cyclophosphamide: Given orally",
        "  filgrastim: Given SC",
        "  paclitaxel albumin-stabilized nanoparticle formulation: Given IV",
        "  trastuzumab: Given IV",
        "  laboratory biomarker analysis: Correlative studies",
        "  quality-of-life assessment: Ancillary studies",
        "  Overall Number of Participants Analyzed: 60",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  56  93.3%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/60 (8.33%)",
        "  Febrile Neutopenia1/60 (1.67%)",
        "  Hemorrhoidal Hemorrhage1/60 (1.67%)",
        "  Mucositis1/60 (1.67%)",
        "  Fever1/60 (1.67%)",
        "  Possible Pneumoncystis Pneumonia1/60 (1.67%)",
        "  Dehydration1/60 (1.67%)",
        "  Musculoskeletal Chest Pain1/60 (1.67%)",
        "  Pneumothorax due to MVA1/60 (1.67%)"
    ]
}